Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L04AB02

ABP 710(infliximab)

Marketing Authorisation Holder: Amgen Europe B.V.

INN: infliximab

Indication

Treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative colitis

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about ABP 710 — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.